{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T07:54:25Z","timestamp":1648540465314},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.medcli.2013.01.018","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T07:02:48Z","timestamp":1365490968000},"page":"273-274","source":"Crossref","is-referenced-by-count":1,"title":["Posible s\u00edndrome neurol\u00e9ptico maligno asociado a aripiprazol e imipramina tratado con bromocriptina"],"prefix":"10.1016","volume":"141","author":[{"given":"Elena","family":"Lopez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Fraile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benito","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.01.018_bib0005","first-page":"181","article-title":"S\u00edndrome neurol\u00e9ptico maligno","volume":"102","author":"Mart\u00ednez","year":"1994","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.01.018_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1130-6343(06)73986-1","article-title":"S\u00edndrome neurol\u00e9ptico maligno asociado a antidepresivos tric\u00edclicos","volume":"30","author":"Toro-Chico","year":"2006","journal-title":"Farm Hosp"},{"key":"10.1016\/j.medcli.2013.01.018_bib0015","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1176\/ps.49.9.1163","article-title":"Neuroleptic malignant syndrome: A review","volume":"49","author":"Pelonero","year":"1998","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.medcli.2013.01.018_bib0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7125(16)30278-4","article-title":"Neuroleptic malignant syndrome","volume":"77","author":"Caroff","year":"1993","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.medcli.2013.01.018_bib0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.v65n0403","article-title":"Neuroleptic malignant syndrome and atypical antipsychotic drugs","volume":"65","author":"Ananth","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.medcli.2013.01.018_bib0030","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1176\/appi.ajp.2008.08101485","article-title":"Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics","volume":"166","author":"Ladds","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.medcli.2013.01.018_bib0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1089\/cap.2004.14.481","article-title":"Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine","volume":"14","author":"Hanft","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.medcli.2013.01.018_bib0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.pnpbp.2009.12.022","article-title":"Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine","volume":"34","author":"Dassa","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.medcli.2013.01.018_bib0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.schres.2006.03.031","article-title":"Aripiprazole and the neuroleptic malignant syndrome","volume":"85","author":"Strawn","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.medcli.2013.01.018_bib0050","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1345\/aph.1L066","article-title":"Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome","volume":"42","author":"Stevens","year":"2008","journal-title":"Ann Pharmacother"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313000845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313000845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T03:02:41Z","timestamp":1539745361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313000845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0025775313000845"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.01.018","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}